Published on
Oct 30, 2025
Medicus Pharma, Gorlin Syndrome Alliance partner to expand SKINJECT access
Medicus Pharma (NASDAQ:MDCX) has partnered with the Gorlin Syndrome Alliance (GSA) to expand compassionate access to its investigational microneedle therapy, SKINJECT, for patients suffering from Gorlin Syndrome, a rare genetic condition that causes …
Source:
Proactive USA
-
Indeterminate
)
